Sold as Tavneos. Every FDA application for this active ingredient.
As of Nov 14, 2026, FDA lists 1 application for Avacopan (sold as Tavneos), first approved Oct 7, 2021, with 0 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Tavneos | Part D | $197M | +159% | 1,879 |
| Pharmacokinetics Of Emulsified Avacopan Applied By NG TubeDiffuse Alveolar Hemorrhage, Antineutrophil Cytoplasmic Antibody Positive Vasculitis · Mayo Clinic | Phase 1 | Recruiting | Apr 29, 2026 |
| Avacopan Added to Standard-of-care Therapy in ANCA-associated Vasculitis With Severe Kidney InvolvementANCA-Associated Vasculitis (AAV) · University Hospital, Toulouse | Phase 3 | Not yet recruiting | Jan 28, 2026 |
| TAVNEOS for Otolaryngologic Manifestations of Granulomatosis With PolyangiitisGranulomatosis With Polyangiitis, Wegener's · Robert Spiera, MD | Phase 2 / Phase 3 | Recruiting | Sep 16, 2025 |
| Early-access Avacopan in Real-world ANCA-associated VasculitisANCA Associated Vasculitis · Leiden University Medical Center | — | Recruiting | Jan 27, 2025 |
| Special Drug Use-results Survey for Long-term Use（Avacopan）Microscopic Polyangiitis (MPA), Granulomatosis With Polyangiitis (GPA) · Kissei Pharmaceutical Co., Ltd. | — | Recruiting | Jan 3, 2025 |
| Avacopan in Crescentic Immunoglobulin A Nephropathy (IgAN)IgA Nephropathy (IgAN) · Mayo Clinic | Phase 2 | Recruiting | Nov 6, 2024 |
| Avacopan vs Reduced-dose Glucocorticoids in ANCA-associated VasculitisANCA Associated Vasculitis (AAV) · Chiba University | Phase 4 | Recruiting | Sep 25, 2024 |
| Study to Evaluate Avacopan in Combination With a Rituximab or Cyclophosphamide-containing Regimen, in Children From 6 Years to < 18 Years of Age With AAV.Vasculitis · Amgen | Phase 3 | Active, not recruiting | Mar 20, 2024 |
| Approved | Application | Sponsor | Supplements | Marketing |
|---|---|---|---|---|
| Oct 7, 2021 | TavneosNDA 214487 · New molecular entity | Chemocentryx | 2 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
